Refine by
Brain Monitor Articles & Analysis
21 news found
Sydney, Australia - November 23, 2022 - Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that Imperial College London has released additional data related to the F-18 Pivalate (RAD 101) Phase 2a imaging trial in patients with brain metastases. High contrast ...
Smart helmets with embedded brainwave monitoring technology will automate the detection of concussions for caregivers on the sidelines. There is a high unmet need that is not properly addressed by motion sensors which have proven to be clinically unreliable in monitoring brain injury. Find out more about NoMo technology (here). ...
Beacon Biosignals, which applies AI to EEG to unlock precision medicine for brain conditions, today announced a partnership with Stratus, the nation's leading provider of EEG services, to enable expanded clinical trial service capabilities by leveraging Beacon's machine learning neuroanalytics platform. ...
CINCINNATI, OH – March 30, 2022 – Sense Neuro Diagnostics, a medical technology company focused on improving outcomes for stroke and brain injury patients, has been selected to participate in the Mayo Clinic and Arizona State University MedTech Accelerator. The flagship program of the Mayo Clinic and ASU Alliance for Health Care was designed to provide early-stage medical device and ...
First Quarter and Recent Business Updates Submitted clearance request to FDA for less than 30-day use of NeuroOne's Evo® sEEG Electrode, which has already been 510(k) cleared for temporary (less than 24 hours) use Exhibited our Evo cortical electrode product family at the American Epilepsy Society Meeting in Zimmer Biomet's booth Presented poster with the following title at American ...
Clinical trial underway at five US hospital sites to evaluate Sense’s novel, non-invasive brain scanner to monitor intracranial hemorrhage in acute hospital setting Drug Controller General of India (DCGI) and Health Canada grant permission to conduct clinical trial at multiple sites in India and Canada Current standard of care lacks a means to ...
NeuSTAT™ is currently in a pivotal trial for continuous monitoring of brain injury in an acute care setting. NeuroHawk™ EMS (expected to begin pivotal trial in 2022) is being developed as a triage tool for first responders, enabling detection of traumatic brain injury and stroke by subtype. ...
For the August installment of the Healthtech Leader of the Month series, we interviewed Aswin Gunasekar, founder and CEO of Zeto. Zeto is a device-driven platform for acquiring, accessing, and interpreting electroencephalograms (EEGs). An EEG is a test used to evaluate electrical activity in the ...
Department of Defense will accelerate development of a new rapid, noninvasive brain scanner that can detect and continuously monitor traumatic brain injury in a battlefield or field environment. ...
PrecivityAD™ Blood Test Relies on Proprietary Platform The PrecivityAD™ test identifies whether a patient is likely to have amyloid plaques in the brain. The test relies on precise quantitation of the Amyloid Beta 42/40 ratio (Aβ 42/40) and detection of the Apolipoprotein E proteotype (equivalent to ApoE genotype) in blood samples, using C2N’s proprietary ...
Starting with the PrecivityAD™ blood test, it’s possible to identify brain amyloid plaques from a single sample of blood and to aid in the early diagnosis of Alzheimer’s disease. ...
C2N Diagnostics, which offers the PrecivityAD™ blood test that can help detect if certain markers for Alzheimer’s disease are in the brain, now has its analytical validation results available for review. ...
” Each year nearly 800,000 people suffer strokes in the United States and 1.7 million Americans suffer traumatic brain injury. Ongoing or repeat bleeding in the brain contributes to decreased brain function and disability and may be difficult to detect under the current standard of care. There is currently no objective way to detect ...
Even with the heterogeneity of samples, we found the test reliably detected brain amyloid — this speaks to the test’s robustness.” PrecivityAD™ is the first widely accessible blood test to help physicians with diagnosing Alzheimer’s disease. ...
” PrecivityAD™ Blood Test Relies on Proprietary Platform The PrecivityAD™ test identifies whether a patient is likely to have amyloid plaques in the brain. The test relies on precise quantitation of the amyloid beta 42/40 ratio (Aβ 42/40) and detection of the apolipoprotein E proteotype (equivalent to ApoE genotype) in blood samples, using C2N’s ...
The company is also moving ahead with development of a Brain Health Panel that seeks to detect multiple blood-based markers for Alzheimer’s disease to aid in better disease staging, treatment monitoring, and differential diagnosis. ...
Electroencephalography (EEG) devices are incredibly helpful in diagnosing and monitoring certain brain disorders, such as epilepsy and strokes. However, they are not particularly user-friendly or convenient, with specialized technicians performing time consuming procedures, such as skin preparation, to get patients ready to undergo the procedure. ...
Methodist Le Bonheur Healthcare (MLH) is the first hospital system globally to participate in a landmark study using a first-of-its-kind EEG device. EEG stands for electroencephalogram. EEG tests are conducted to detect problems in the brain that may be associated with certain brain disorders such as seizures, tumors or strokes. A typical EEG test consists of multiple electrodes attached to a ...
Patent Application No. 16/044,279 entitled "miRNA-based methods for detecting and monitoring aging." The patent covers the use of methods developed by DiamiR based on targeted quantitative analysis of microRNAs enriched in the brain and detectable in blood plasma as biomarkers of brain aging. ...
ByDiamiR
The SPEAC® System is the first FDA-cleared, non-EEG, physiological, signal-based system for seizure monitoring. "We are excited and thrilled by this award from Popular Science," said Mike Girouard, President, CEO and co-founder of Brain Sentinel, Inc. ...